Literature DB >> 25132746

Prognostic relevance of minimal residual disease in colorectal cancer.

Ulrich Bork1, Robert Grützmann1, Nuh N Rahbari1, Sebastian Schölch1, Marius Distler1, Christoph Reissfelder1, Moritz Koch1, Jürgen Weitz1.   

Abstract

Presence of occult minimal residual disease in patients with colorectal cancer (CRC) has a strong prognostic impact on survival. Minimal residual disease plays a major role in disease relapse and formation of metastases in CRC. Analysis of circulating tumor cells (CTC) in the blood is increasingly used in clinical practice for disease monitoring of CRC patients. In this review article the role of CTC, disseminated tumor cells (DTC) in the bone marrow and micrometastases and isolated tumor cells (ITC) in the lymph nodes will be discussed, including literature published until September 2013. Occult disease is a strong prognostic marker for patient survival in CRC and defined by the presence of CTC in the blood, DTC in the bone marrow and/or micrometastases and ITC in the lymph nodes. Minimal residual disease could be used in the future to identify patient groups at risk, who might benefit from individualized treatment options.

Entities:  

Keywords:  Circulating tumor cells; Colorectal cancer; Disseminated tumor cells; Isolated tumor cells; Micrometastases; Minimal residual disease; Occult disease

Mesh:

Year:  2014        PMID: 25132746      PMCID: PMC4130837          DOI: 10.3748/wjg.v20.i30.10296

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  65 in total

1.  [S3-guideline colorectal cancer version 1.0].

Authors:  C Pox; S Aretz; S C Bischoff; U Graeven; M Hass; P Heußner; W Hohenberger; A Holstege; J Hübner; F Kolligs; M Kreis; P Lux; J Ockenga; R Porschen; S Post; N Rahner; A Reinacher-Schick; J F Riemann; R Sauer; A Sieg; W Scheppach; W Schmitt; H J Schmoll; K Schulmann; A Tannapfel; W Schmiegel
Journal:  Z Gastroenterol       Date:  2013-08-16       Impact factor: 2.000

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Detection methods of circulating tumor cells.

Authors:  Klaus Pantel; Catherine Alix-Panabières
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

Review 4.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

Review 5.  Essentials of circulating tumor cells for clinical research and practice.

Authors:  Marian Liberko; Katarina Kolostova; Vladimir Bobek
Journal:  Crit Rev Oncol Hematol       Date:  2013-07-05       Impact factor: 6.312

6.  Circulating tumour cells in non-metastatic breast cancer: a prospective study.

Authors:  Anthony Lucci; Carolyn S Hall; Ashutosh K Lodhi; Anirban Bhattacharyya; Amber E Anderson; Lianchun Xiao; Isabelle Bedrosian; Henry M Kuerer; Savitri Krishnamurthy
Journal:  Lancet Oncol       Date:  2012-06-06       Impact factor: 41.316

7.  Colonic neoplasms in mice produced with six injections of 1,2-dimethylhydrazine.

Authors:  E E Deschner; F C Long
Journal:  Oncology       Date:  1977       Impact factor: 2.935

8.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Authors:  Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol
Journal:  J Clin Oncol       Date:  2008-07-01       Impact factor: 44.544

9.  Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.

Authors:  Jing Yang; Sendurai A Mani; Joana Liu Donaher; Sridhar Ramaswamy; Raphael A Itzykson; Christophe Come; Pierre Savagner; Inna Gitelman; Andrea Richardson; Robert A Weinberg
Journal:  Cell       Date:  2004-06-25       Impact factor: 41.582

10.  Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.

Authors:  Ellen Heitzer; Martina Auer; Christin Gasch; Martin Pichler; Peter Ulz; Eva Maria Hoffmann; Sigurd Lax; Julie Waldispuehl-Geigl; Oliver Mauermann; Carolin Lackner; Gerald Höfler; Florian Eisner; Heinz Sill; Hellmut Samonigg; Klaus Pantel; Sabine Riethdorf; Thomas Bauernhofer; Jochen B Geigl; Michael R Speicher
Journal:  Cancer Res       Date:  2013-03-07       Impact factor: 12.701

View more
  20 in total

1.  A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer.

Authors:  Alexander M Betzler; Susan Kochall; Linda Blickensdörfer; Sebastian A Garcia; May-Linn Thepkaysone; Lahiri K Nanduri; Michael H Muders; Jürgen Weitz; Christoph Reissfelder; Sebastian Schölch
Journal:  J Vis Exp       Date:  2017-07-06       Impact factor: 1.355

2.  Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer.

Authors:  Susan Kochall; May-Linn Thepkaysone; Sebastián A García; Alexander M Betzler; Jürgen Weitz; Christoph Reissfelder; Sebastian Schölch
Journal:  J Vis Exp       Date:  2017-07-18       Impact factor: 1.355

3.  Impact of the Pringle manoeuvre on the mitochondrial redox state of hepatocytes in colorectal cancer patients with liver metastases.

Authors:  Anton Burlaka; Ariadna Paliichuk; Dmytro Makhmudov; Andrii Lukashenko
Journal:  Contemp Oncol (Pozn)       Date:  2021-10-14

Review 4.  Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches.

Authors:  Carlotta Ceccon; Valentina Angerilli; Cosimo Rasola; Letizia Procaccio; Marianna Sabbadin; Francesca Bergamo; Umberto Malapelle; Sara Lonardi; Matteo Fassan
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

Review 5.  Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.

Authors:  Alexios-Fotios A Mentis; Petros D Grivas; Efthimios Dardiotis; Nicholas A Romas; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2020-04-24       Impact factor: 9.261

Review 6.  The State of the Art in Colorectal Cancer Molecular Biomarker Testing.

Authors:  Raju K Pillai; Jean R Lopategui; Deepti Dhall; Maha Guindi; Thomas Slavin; Catherine E Lofton-Day; Scott D Patterson
Journal:  Adv Anat Pathol       Date:  2016-03       Impact factor: 3.875

7.  May CTC technologies promote better cancer management?

Authors:  Martin Pesta; Vlastimil Kulda; Andrea Narsanska; Jakub Fichtl; Ondrej Topolcan
Journal:  EPMA J       Date:  2015-01-22       Impact factor: 6.543

8.  Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection.

Authors:  Gregor Norcic; Franc Jelenc; Petra Cerkovnik; Vida Stegel; Srdjan Novakovic
Journal:  Oncol Lett       Date:  2016-09-01       Impact factor: 2.967

9.  Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer.

Authors:  Sebastian Schölch; Sebastián A García; Naoki Iwata; Thomas Niemietz; Alexander M Betzler; Lahiri K Nanduri; Ulrich Bork; Christoph Kahlert; May-Linn Thepkaysone; Anka Swiersy; Markus W Büchler; Christoph Reissfelder; Jürgen Weitz; Nuh N Rahbari
Journal:  Oncotarget       Date:  2016-05-10

10.  Preoperative endoscopic localization of colorectal cancer and tracing lymph nodes by using carbon nanoparticles in laparoscopy.

Authors:  Qingxuan Wang; Endong Chen; Yefeng Cai; Chong Chen; Wenxu Jin; Zhouci Zheng; Yixiang Jin; Yao Chen; Xiaohua Zhang; Quan Li
Journal:  World J Surg Oncol       Date:  2016-08-30       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.